Since SUMOylation inhibitors synergize with FXR agonists in inhibiting HSCs activation, these inhibitors may also potentiate the therapeutic FXR agonist decrease of liver fibrosis. This evidence concerns the gene NR1H4 and Hepatic fibrosis.